SJS Investment Consulting’s ARS Pharmaceuticals SPRY Stock Holding History

SJS Investment Consulting’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9	Buy	+1	New	+$9	﹤0.01%	2860

Other funds holding SPRY

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Cambridge Investment Research Advisors

Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return

Norman Fields Gottscho Capital Management New York $330M AUM 27.75% 1-Year Est. Return

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return

SJS Investment Consulting's SPRY Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 1 share worth $9. The stake represents ﹤0.01% of the portfolio and ranks #2860 among its holdings.

27 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

SJS Investment Consulting held 1 share of ARS Pharmaceuticals worth $9 as of Q2 2026.
ARS Pharmaceuticals was a new SJS Investment Consulting position in Q2 2026.
ARS Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2860 holding.
27 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.